AC Immune's PET tracer to be presented at AAIC

2019 12 09 23 14 2273 Brain Dementia Leaves 400

A researcher from Swiss biopharmaceutical company AC Immune will present findings on the company's alpha-synuclein-PET tracer program at the virtual 2020 Alzheimer's Association International Conference (AAIC).

During a 28 June presentation, AC Immune research scientist Francesca Capotosti, PhD, will discuss the development of a PET tracer for the diagnosis of a‑synucleinopathies, which can help in the diagnosis of Parkinson's disease. The presentation will take place during a panel covering non-Alzheimer's neurodegenerative disorders at the conference.

The company will also have research on a phase IB clinical trial of its anti-Abeta vaccine ACI-24 presented at AAIC. The trial is the first large, multinational study on clinical and biomarker changes of Down-syndrome-related Alzheimer's disease, according to AC Immune.

Page 1 of 551
Next Page